Cases & Deals

  • Home
  • Practices
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Mylan

Share

Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Mylan

September 2017

Client(s) Purdue Pharma L.P.

Jones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief. Purdue came to a successful resolution of the dispute through settlement.

Purdue Pharma et al. v. Mylan Pharmaceuticals Inc., et al., Case No. 1:15-cv-01155-SLR (D. Del.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.